Research programme: African swine fever virus vaccines - Aridis Pharmaceuticals
Latest Information Update: 28 Apr 2025
At a glance
- Originator Aridis Pharmaceuticals
- Developer Aridis Pharmaceuticals; Kermode Biotechnologies
- Class Monoclonal antibodies; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Arbovirus infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for research development in Arbovirus-infections(Prevention) in USA (Parenteral)
- 08 Mar 2021 Aridis Pharmaceuticals and Kermode Biotechnologies enters out-licensing and product discovery agreement to develop APEX technology based vaccines and monoclonal antibodies
- 08 Mar 2021 Early research in Arbovirus infections ( African swine fever virus infections) (Prevention) in USA (Parenteral)